Cargando…
PCV13 Pediatric Routine Schedule Completion and Adherence Before and During the COVID-19 Pandemic in the United States
INTRODUCTION: A 13-valent pneumococcal conjugate vaccine (PCV13) was licensed to protect against emerging Streptococcus pneumoniae serotypes. Healthcare services, including routine childhood immunizations, were disrupted as a result of coronavirus disease 2019 (COVID-19). This study compared PCV13 r...
Autores principales: | Huang, Liping, Nguyen, Jennifer L., Alfred, Tamuno, Perdrizet, Johnna, Cane, Alejandro, Arguedas, Adriano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552144/ https://www.ncbi.nlm.nih.gov/pubmed/36219342 http://dx.doi.org/10.1007/s40121-022-00699-5 |
Ejemplares similares
-
1179. PCV13 Pediatric Routine Schedule Completion and Adherence Before and During the COVID-19 Pandemic in the US
por: Huang, Liping, et al.
Publicado: (2021) -
101. PCV13 Pediatric Vaccination Disparity and Impact Due to COVID-19 Pandemic in the US
por: Huang, Liping, et al.
Publicado: (2021) -
576. Burden of Pneumococcal Disease Due to Serotypes Covered by the 13-Valent and New Higher-Valent Pneumococcal Conjugate Vaccines in All Children and Children at Risk in the United States
por: Huang, Liping, et al.
Publicado: (2022) -
Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population
por: Lytle, Derek, et al.
Publicado: (2023) -
Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants
por: Perdrizet, Johnna, et al.
Publicado: (2020)